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Abstract
CaMKII is a remarkably complex protein kinase, known to have a fundamental role in synaptic plasticity and
memory formation. Further, CaMKII has also been suggested to be a tau kinase. CaMKII dysregulation may therefore
be a modulator of toxicity in Alzheimer’s disease, a dementia characterised by aberrant calcium signalling, synapse
and neuronal loss, and impaired memory. Here, we first examine the evidence for CaMKII dysregulation in Alzheimer’s
patients and draw parallels to findings in disease models which recapitulate key aspects of the disease. We then put
forward the hypothesis that these changes critically contribute to neurodegeneration and memory impairment in
Alzheimer’s disease.
Keywords: CaMKII, Alzheimer’s disease, Post-mortem brain, Autophosphorylation, Memory, Tau
Background
The most common form of adult dementia, Alzheimer’s
disease (AD) is characterised by progressive loss of
selective cognitive functions, particularly those related to
memory. It was in the early 20th century that Alois
Alzheimer first described the presence of ‘positive’
lesions such as senile plaques (SPs) and neurofibrillary
tangles (NFTs) in the brain of a patient suffering from
dementia (for a translation see [1]). However, it was not
until the mid- to late 1980s that these were found to
comprise aggregated amyloid-β (Aβ) peptides [2–4] and
hyperphosphorylated tau protein [5–8], respectively.
Although AD pathogenesis is yet to be fully elucidated,
it has been posited that the Aβ peptide is central to
disease onset. The “amyloid cascade” hypothesis suggests
that Aβ, resulting from aberrant cleavage of the amyloid
precursor protein (APP) by β- and γ-secretases, can
aggregate into a toxic species, leading to a series of
events that culminate in AD pathology [9, 10]. New evi-
dence suggests alternative proteolytic pathways of APP by
η-secretases can lead to production of a toxic amyloid-η
(Aη) species that can also contribute to AD pathology [11].
While SPs and NFTs are useful diagnostic markers
during post-mortem examination, it is actually the occur-
rence of ‘negative’ lesions such as synaptic loss, which
precedes neuronal loss, that best correlates with the ad-
vancement of cognitive decline. Several reports have noted
the progressive loss of synaptic boutons and other synap-
tic elements in brains of patients with symptoms ranging
from mild cognitive impairment (MCI) to early-mild AD
[12–17]. Hippocampal and cortical regions show the most
marked loss of these features, reflecting their importance
in processes of memory formation and storage. The pre-
cise mechanism by which synaptic dysfunction occurs in
the AD brain is unknown; in vitro studies have shown that
Aβ oligomers can directly bind to synaptic sites [18] and
reduce long-term potentiation (LTP) [19–21], while facili-
tating long-term depression (LTD) [22]. Aβ oligomers can
compromise synaptic function at both pre- and post-
synaptic sites, but their early targets may in fact be exci-
tatory post-synapses [23], where they can alter several
signalling pathways.
There is significant evidence that intracellular calcium
(Ca2+) homeostasis is disrupted in both sporadic and
familial forms of AD, and can exacerbate Aβ formation
and promote tau hyperphosphorylation (for reviews see
[24, 25]). Additionally Aβ can influence cellular path-
ways involved in Ca2+ buffering, compromising the abil-
ity of neurons to respond to excitotoxic challenge [26],
suggestive of a pathogenic feed-forward cycle where Aβ
and Ca2+ can concomitantly impair synaptic morph-
ology, trigger neuronal apoptosis, and eventually lead to
deterioration of cognition [27]. The key players in such a
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pathological cascade are most likely molecules that lie
downstream of Ca2+-signalling and are also present in ex-
citatory synapses where Aβ oligomers likely initially bind.
One candidate is the Ca2+/calmodulin (CaM)-dependent
protein kinase II (CaMKII), the major post-synaptic pro-
tein at excitatory synapses. This kinase is fundamentally
important for synaptic plasticity and memory formation.
Here we discuss evidence for the involvement of CaMKII
in AD pathogenesis.
CaMKII: regulation and function
CaMKII is a holoenzyme of 12 subunits, each derived
from one of four genes (α, β, γ and δ) [28]. In rat fore-
brain, αCaMKII and βCaMKII are the most abundant
subunits, with the former expressed 3–4 times more
than the latter [29], and can assemble into homo- or
heteromeric holoenzymes [30]. The expression and func-
tion of α and βCaMKII differ; while α is expressed exclu-
sively in glutamatergic neurons [31], the β subunit is
also expressed in inhibitory interneurons [32]. Further,
βCaMKII, but not α, binds to F-actin, which is relieved
upon activation by Ca2+/CaM [33]. This dissociation is
thought to regulate morphological changes at the syn-
apse [34]. Functionally, αCaMKII activity is essential for
synaptic plasticity and memory formation, as elegantly
demonstrated in knock-in mutant mice [35]. It may also
have a structural role as it can bind to various proteins
at the synapse [36] and its expression is extremely
abundant (about 1.4% of hippocampal protein) [29]. In
contrast, βCaMKII activity is not required for synaptic
plasticity and memory formation [37], indicating that
the primary function of this subunit is structural.
CaMKII holoenzymes are activated by the binding of
Ca2+/CaM, and also by NMDA receptors (NMDARs) and
L-type voltage-gated Ca2+ channels (VGCCs) at the synapse
[38]. An important aspect of αCaMKII activity is its auto-
phosphorylation at threonine-286 (T286) (for review see
[39]). This autophosphorylation results from an interaction
between subunits within the holoenzyme and switches
the subunit activity from a Ca2+/CaM-dependent to –
independent state. This ‘autonomous’ activity persists at the
synapse for about one minute after stimulation [38]. How-
ever, T286 autophosphorylation can last longer and the
dissociation between prolonged autophosphorylation and
autonomous activity is not understood [39, 40]. Studies
with T286 autophosphorylation-deficient knock-in mutants
have shown that this event is fundamentally important for
NMDAR-dependent LTP at hippocampal CA1 synapses
[41–43] but not at perforant path-granule cell synapses
[44]. Furthermore, T286 autophosphorylation is essential
for spatial memory formation [41, 45]. Besides T286
autophosphorylation, αCaMKII is also regulated by other
autophosphorylation events, phosphatase activity and
endogenous inhibitor proteins (for reviews see [36, 46]).
CaMKII abnormalities in AD
Expression analyses of post-mortem disease brain can be
very informative, in that prominent disease-related dys-
function is detectable. In contrast, studies with AD
models, in rodents or in vitro, suffer from inadequate
modelling of disease cause. The limitation of post-
mortem studies is that they may be confounded by post-
mortem delay, which can range from several hours to
one day, during which protein expression may decrease
and, in particular, post-translational protein modifica-
tions such as phosphorylation may be compromised.
Another limitation is that they offer only one time point
for analysis; however the severity of disease at the time
of death can be estimated [47].
Semi-quantitative western blot studies with post-
mortem tissue have suggested that αCaMKII protein
expression level is not altered in hippocampus, frontal
cortex or other cortical areas in the severe stages of
AD [48, 49]. However, immunohistochemical analyses
have indicated that αCaMKII-expressing neurons,
which are excitatory, are selectively lost in hippocam-
pal area CA1 in severe AD [50, 51] (but see [52, 53]).
The remaining excitatory neurons in CA1 appear to
express increased levels of αCaMKII [50, 51]. Interest-
ingly, increased αCaMKII expression is not found in
hippocampal area CA3 in severe AD [51], a region
which has almost no neuronal loss in the end stages
of AD, in stark contrast to substantial neuronal loss
in CA1 [54].
Changes in distribution of CaMKII mRNA in AD
brain are more difficult to determine. One study finds
reduced hybridisation of αCaMKII mRNA in CA1, but
only when neuronal loss associated with severe NFT
formation is observed [55], echoing the findings of
Simonian et al. However another study finds an increase
in hybridisation throughout the AD hippocampus, espe-
cially in the dentate gyrus (DG) and CA3 regions [56]. A
more recent microarray analysis of several brain regions
from AD patients discloses that alterations in the ex-
pression of CaMKII mRNA may be far more composite
than previously thought, with genes encoding different
subunits showing different directions in expression changes
across brain regions [57].
Early western blot studies suggest that autophospho-
rylation of αCaMKII at T286 is reduced in hippocampus
and frontal cortex of the severe AD brain [48]. This is
also reflected by the fact that cortical regions show a
total loss of immunoreactivity for active conformations
of CaM and reduced immunoreactivity for other forms
[58]. However, this result has not been replicated [59].
Instead, it has emerged that in CA3 and the DG of AD
brain, the subcellular localisation of αCaMKII autophos-
phorylation is altered [59]. p(T286)-αCaMKII is specific-
ally decreased in dendrites and synapses, and increased
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in perikarya of CA3 neurons and granule cells of the
DG. This altered distribution correlates with cognitive
impairment both in patients with AD and its prodrome
MCI [59]. Studies using cultured fibroblasts and lym-
phocytes from patients also suggest dysregulated CaM-
KII activity in AD [60, 61].
CaMKII dysregulation in AD models
The study of molecular dysfunction in AD has been
greatly advanced by the development of transgenic
mouse models that recapitulate some AD hallmarks.
However, such models usually overexpress mutated
forms of the human APP gene, and therefore are not
fully representative of the causes underlying AD [62].
Additionally, they are confounded by artefacts due to in-
creased transgene expression, and ageing, the main risk
factor of AD, is not sufficiently addressed. Nonetheless,
if a molecular dysregulation is similar in post-mortem
AD brain and in AD models, it is very likely that it oc-
curs in the disease.
Studies on AD models, like post-mortem analyses,
suggest abnormalities in regulation of CaMKII. One of
the most widely used AD models is the Tg2576 mouse,
which carries the APPSwe mutation (K670N/M671L).
While the total levels of α/βCaMKII are not altered in
the frontal cortex of these mice, there is a significant
alteration in their subcellular distribution, from synapse
to cytosol. This change is not due to synaptic loss and is
also seen in levels of active αCaMKII, suggesting a se-
lective loss of synaptic CaMKII [63]. Another commonly
used mouse model contains mutations in both APP and
presenilin-1 (PS1), a component of the γ-secretase com-
plex. Two studies find altered hippocampal expression
of p(T286)-αCaMKII in these mice, and one additionally
finds reduced levels of the CaMKII-binding VGCC
Cav1.2 and elevated CaM [64, 65]. Altered αCaMKII
distribution is also found in a mouse model of spor-
adic AD in which amyloid oligomers are injected into
the ventricles. This acute treatment results in a shift
of p(T286)-αCaMKII from apical dendrites/spines to
the somata of CA3 pyramidal neurons and is blocked
by inhibition of the phosphatase calcineurin, which aug-
ments phosphatase-1 activity [59].
A calcineurin-dependent redistribution of autopho-
sphorylated αCaMKII also occurs in Aβ oligomer-treated
primary neuronal cultures [59, 63]. Moreover, treating
hippocampal neurons with Aβ oligomers impairs αCaM-
KII activation [64, 66]. In contrast to rodent models, there
is no change in CaM levels and greater expression of
Cav1.2 channels [64], a finding which is confirmed by an
independent study [67]. This may be the result of cell
cultures modelling earlier stages of the disease where
there is no neuronal loss [64], or due to a lack of fully
functional synapses.
Impact of dysregulated CaMKII in AD
Post-mortem analyses and studies with AD models indi-
cate that T286-autophosphorylation of αCaMKII is im-
paired at synapses in the disease. Considering this
autophosphorylation is essential for NMDAR-dependent
LTP at CA1 synapses and spatial memory formation
[41, 42, 45, 68, 69], the redistribution of p(T286)-αCaMKII
could contribute to cognitive impairment in AD. Consist-
ent with this, the reduction of T286-autophosphorylation
in apical dendrites of granule cells of the DG in subjects
with MCI and AD correlates with cognitive dysfunction as
measured by MMSE scores [59]. Moreover, spatial train-
ing of Tg2576 mice increases T286-autophosphorylation
of αCaMKII in the hippocampus and rescues deficits in
contextual memory formation [70], suggesting deficits in
T286 autophosphorylation are key to causing impairments
in synaptic plasticity and memory formation in AD. This
idea is confirmed in studies with Aβ-treated cultured pri-
mary neurons, which have reduced surface expression of
AMPA receptor (AMPAR) subunit GluA1 and impaired
AMPAR-mediated synaptic transmission. Knockdown of
CaMKII mimics these effects and CaMKII overexpression
rescues these [63]. An analogous observation is seen when
treating rat hippocampal slices with Aβ1-42, where Aβ
inhibits CaMKII activation and blocks the stimulation-
dependent phosphorylation of a CaMKII-specific site on
GluA1 [71]. Furthermore, it has been suggested that
neurotrophin-induced enhancement of p(T286)-αCaMKII
leads to rescue of Aβ-induced deficits in LTP at hippo-
campal synapses [72].
At the neuropathological level, the finding that APP
can be phosphorylated in vitro by several kinases includ-
ing CaMKII [73], puts forward the hypothesis that there
could be a possible link between CaMKII and Aβ pro-
duction. Both McKee and Wang remark on some co-
localisation of αCaMKII with SPs, with differences in the
deposition pattern around diffuse and neuritic plaques
[50, 51]. It has been found that phosphorylation on T668
of APP is elevated in AD brain and can regulate its cleav-
age by β-secretases [74], but this is not known to be a
CaMKII site of phosphorylation. It has also been sug-
gested that phosphorylation of CaMKII sites (T654/S655)
can alter the conformation of APP [75] and regulate its
trafficking [76], but direct evidence that CaMKII is
involved is lacking.
The correlation between CaMKII and tau phosphoryl-
ation is much stronger. Increased αCaMKII expression
in CA1 neurons [50, 51] and increased αCaMKII au-
tophosphorylation in cell bodies of CA3 neurons and
granule cells in the DG [59, 63] suggest that outside
of synapses, αCaMKII is hyperactive. Being a tau kinase,
this hyperactivity could contribute to NFT formation.
NFTs are made of paired helical filaments (PHFs) which
contain tau protein hyperphosphorylated at many sites
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[77]. Several analyses of AD brain find that αCaMKII
expression in cell bodies frequently co-localises with NFTs
or tau mRNA [50, 51, 53, 55, 78, 79]. Mass spectrometry
has also revealed that AD brain tau is phosphorylated by
CaMKII at several different sites [80]. CaMKII phos-
phorylation of tau alters its electrophoretic mobility
and structure, in a manner specific to PHF-tau [81–83].
Additionally, isolation of PHFs from AD brains results in
co-purification with αCaMKII, 4–7 times more than is
observed in controls [78]. The difficulty in analysing the
importance of CaMKII in tau hyperphosphorylation arises
from the fact that tau can be phosphorylated by several
other kinases at CaMKII sites. It has been found that
phosphorylation by CaMKII alone only partially inhibits
binding of tau to microtubules [84]. Additionally several
post-mortem studies note that not all αCaMKII-
expressing neurons develop NFTs [51, 53, 55], suggesting
that other tau kinases/phosphatases are involved. A likely
scenario is one where αCaMKII phosphorylation of tau
can prime its phosphorylation by other kinases such as
cdk5 and GSK3-β [85, 86]. Collectively, it is conceivable
that CaMKII can contribute to NFT formation in AD.
The loss of synaptic proteins in AD, combined with
dysregulated CaMKII, may also lead to neuronal death. It
has been suggested that αCaMKII and the post-synaptic
protein PSD-95 can compete for binding to the C-
terminus of the NMDAR subunit NR2A upon physio-
logical stimulus [87]. Treating hippocampal neurons with
antisense oligonucleotides to PSD-95 leads to increased
association of both total and p(T286)-αCaMKII with
NR2A/B subunits, although the total levels of αCaMKII
are unaltered [88]. This is paralleled by an increase in cell
death which can be rescued by pharmacological inhibition
of CaMKII. Interestingly, hippocampal neurons are more
susceptible to this type of injury than cortical neurons,
and in organotypic hippocampal slices, CA1 neurons
show greater susceptibility than CA3 or DG neurons. This
reflects the hierarchical decline of brain areas during dis-
ease progression [54], further suggesting that αCaMKII/
NR2A co-expression may be a causal factor for cell death
in AD. Additionally, selectively inhibiting CaMKII in Aβ-
treated primary cortical cultures reduces amyloid-induced
activity of caspases-2 and -3 as well as tau phosphoryl-
ation [89]. It is conceivable that the upregulation of
αCaMKII in CA1 may be directly responsible for the
severe atrophy seen in this region. CaMKII may also be
involved in other signalling cascades related to neuronal
decline [90–93].
Fig. 1 αCaMKII is dysregulated in the Alzheimer’s disease hippocampus. αCaMKII-expressing neurons are selectively lost in the hippocampal
CA1 subfield in AD [50, 51], a region that shows devastating atrophy when compared to age-matched controls [54]. Remaining pyramidal neurons
of this region show increased expression of αCaMKII. This increased expression may critically contribute to tau hyperphosphorylation and other
neurodegenerative processes, such as caspase-3 overactivation, in CA1 pyramidal neurons [for references, see main text]. On the other hand,
CA3 pyramidal neurons and granule cells of the DG do not develop these changes in total αCaMKII. They do however show a change in subcellular
distribution of T286-autophosphorylated αCaMKII (inset) [59]. This change is suggested to shift CaMKII activity from the synapse to soma leading to
synaptic deficits, neurodegenerative processes, and impaired memory formation. AD, Alzheimer’s disease; CA1/3, Cornu Amonis areas 1/3; αCaMKII,
α subunit of calcium/calmodulin-dependent protein kinase II; DG, dentate gyrus
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Conclusions
It has been established that CaMKII is dysregulated in
AD hippocampus (Fig. 1). We suggest that this dysregu-
lation is a key contributor to synaptic degeneration, NFT
formation and memory deficits. However, the nature of
CaMKII dysregulation is undoubtedly complex and
several questions remain unanswered. One key question
is ‘how’ this dysregulation can occur. So far, the focus
has been on levels of total or T286 autophosphorylated
αCaMKII. Other aspects of CaMKII regulation and ac-
tivity need to be addressed, such as distribution of
unphosphorylated CaMKII in AD brain, and other im-
portant sites of autophosphorylation such as T305/6.
Other subunits such as β and γ may also be integral to
CaMKII dysregulation. For example, βCaMKII autophos-
phorylation can regulate its dissociation from F-actin,
thereby allowing cytoskeletal remodelling in glutamater-
gic excitatory synapses, a necessary occurrence for LTP
induction [94]. Impaired Ca2+ signalling could therefore
impact upon both this dissociation and the reassociation
between βCaMKII and F-actin, an event crucial for sta-
bilisation of newly remodelled actin and LTP mainten-
ance. Additionally, γCaMKII can act as a Ca2+/CaM
shuttle to the nucleus to alter gene expression (for
review see [95]). Another fundamental issue is how
CaMKII is dysregulated specifically in the CA1 region,
an area showing devastating neuronal loss in AD com-
pared to normal ageing. Is increased αCaMKII expres-
sion in remaining CA1 neurons a compensatory effect or
a precursor to neurotoxicity? How does this relate to the
subcellular distribution of total and p(T286) αCaMKII in
CA1, and are these changes also calcineurin-dependent?
Finally, it remains to be determined whether CaMKII is
essential for synaptic dysfunction, cognitive impairment
and NFT formation in AD. Can restoring synaptic activity
of CaMKII in models of AD prevent cognitive dysfunc-
tion? Can reducing somatic CaMKII in an in vivo model
of tau pathology prevent or abolish tangle formation?
Elucidating these questions will investigate the hypothesis
that dysregulated CaMKII is a key contributor to synaptic
dysfunction, neurodegeneration and memory impairment
in AD, and may point to novel treatment routes.
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